BIOVENTUS INC - A (BVS)
US09075A1088 - Common Stock
We assign a fundamental rating of 2 out of 10 to BVS. BVS was compared to 192 industry peers in the Health Care Equipment & Supplies industry. BVS has a bad profitability rating. Also its financial health evaluation is rather negative. BVS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BVS had negative earnings in the past year.
In the past year BVS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BVS reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BVS reported negative operating cash flow in multiple years.
1.2 Ratios
BVS has a Return On Assets (-22.45%) which is comparable to the rest of the industry.
The Return On Equity of BVS (-102.59%) is worse than 70.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.45% | ||
| ROE | -102.59% | ||
| ROIC | N/A |
ROA(3y)-3.03%
ROA(5y)-2.66%
ROE(3y)-14.27%
ROE(5y)-11.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BVS has a Gross Margin of 62.87%. This is in the better half of the industry: BVS outperforms 60.94% of its industry peers.
BVS's Gross Margin has declined in the last couple of years.
BVS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.08%
GM growth 5Y-2.1%
2. Health
2.1 Basic Checks
BVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for BVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.42, we must say that BVS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.42, BVS perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
A Debt/Equity ratio of 2.11 is on the high side and indicates that BVS has dependencies on debt financing.
BVS has a worse Debt to Equity ratio (2.11) than 85.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.42 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
A Current Ratio of 1.55 indicates that BVS should not have too much problems paying its short term obligations.
BVS has a Current ratio of 1.55. This is amonst the worse of the industry: BVS underperforms 83.33% of its industry peers.
A Quick Ratio of 0.94 indicates that BVS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.94, BVS is doing worse than 86.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for BVS have decreased strongly by -127.08% in the last year.
The Revenue has decreased by -2.69% in the past year.
BVS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.88% yearly.
EPS 1Y (TTM)-127.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-37.5%
Revenue 1Y (TTM)-2.69%
Revenue growth 3Y14.62%
Revenue growth 5Y11.88%
Revenue growth Q2Q-6.14%
3.2 Future
Based on estimates for the next years, BVS will show a very strong growth in Earnings Per Share. The EPS will grow by 35.88% on average per year.
BVS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.18% yearly.
EPS Next Y-137.87%
EPS Next 2Y-0.55%
EPS Next 3Y33.47%
EPS Next 5Y35.88%
Revenue Next Year-3.43%
Revenue Next 2Y0.9%
Revenue Next 3Y2.71%
Revenue Next 5Y3.18%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
BVS is valuated quite expensively with a Price/Forward Earnings ratio of 25.47.
Based on the Price/Forward Earnings ratio, BVS is valued a bit cheaper than 79.17% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.92. BVS is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BVS is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 14.78 |
4.3 Compensation for Growth
A more expensive valuation may be justified as BVS's earnings are expected to grow with 33.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.55%
EPS Next 3Y33.47%
5. Dividend
5.1 Amount
BVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOVENTUS INC - A
NASDAQ:BVS (5/2/2024, 9:02:16 AM)
4.03
+0.04 (+1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap319.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.47 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.45% | ||
| ROE | -102.59% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.87% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.55 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-127.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-137.87%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.69%
Revenue growth 3Y14.62%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y